MX366223B - Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. - Google Patents

Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.

Info

Publication number
MX366223B
MX366223B MX2015006548A MX2015006548A MX366223B MX 366223 B MX366223 B MX 366223B MX 2015006548 A MX2015006548 A MX 2015006548A MX 2015006548 A MX2015006548 A MX 2015006548A MX 366223 B MX366223 B MX 366223B
Authority
MX
Mexico
Prior art keywords
repeat domains
binding proteins
against her2
domains against
repeat
Prior art date
Application number
MX2015006548A
Other languages
English (en)
Other versions
MX2015006548A (es
Inventor
Fiedler Ulrike
Strobel Heike
Dolado Igancio
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of MX2015006548A publication Critical patent/MX2015006548A/es
Publication of MX366223B publication Critical patent/MX366223B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)

Abstract

La presente invención se refiere a una proteína vinculante o de unión, recombinante, que comprende al menos un primer y un segundo dominio de repetición, en donde cada uno de dichos dos dominios de repetición se vincula o une a la región extracelular del HER2 y en donde dichos dominios de repetición se vinculan o unen covalentemente.
MX2015006548A 2012-11-30 2013-12-02 Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. MX366223B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195156.0A EP2738180A1 (en) 2012-11-30 2012-11-30 Binding proteins comprising at least two binding domains against HER2.
PCT/EP2013/075290 WO2014083208A1 (en) 2012-11-30 2013-12-02 Binding proteins comprising at least two repeat domains against her2

Publications (2)

Publication Number Publication Date
MX2015006548A MX2015006548A (es) 2015-10-15
MX366223B true MX366223B (es) 2019-07-03

Family

ID=47257683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006548A MX366223B (es) 2012-11-30 2013-12-02 Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.

Country Status (11)

Country Link
US (1) US10370414B2 (es)
EP (2) EP2738180A1 (es)
JP (1) JP6410724B2 (es)
KR (1) KR102290592B1 (es)
CN (1) CN104918959A (es)
AU (2) AU2013351096C9 (es)
CA (1) CA2892747C (es)
HK (1) HK1211297A1 (es)
MX (1) MX366223B (es)
RU (1) RU2664464C9 (es)
WO (1) WO2014083208A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CN113278077A (zh) * 2010-11-26 2021-08-20 分子组合公司 设计的与血清白蛋白结合的重复蛋白
CA2883264A1 (en) * 2012-10-15 2014-04-24 Universitat Zurich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
EP4570318A3 (en) 2013-11-27 2025-10-15 Zymeworks BC Inc. Bispecific antigen-binding constructs targeting her2
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
EP3253785B1 (en) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
BR112017020986A2 (pt) * 2015-04-02 2018-08-14 Molecular Partners Ag. proteínas de ligação recombinantes e seu uso
CN107922483B (zh) 2015-07-16 2021-07-30 纳维格蛋白质有限公司 新型免疫球蛋白结合蛋白及其在亲和纯化中的用途
WO2017013136A1 (en) * 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
JP6881760B2 (ja) * 2015-07-20 2021-06-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質に基づくＨｅｒ２結合タンパク質
AU2017260274A1 (en) 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
RU2627215C1 (ru) * 2016-05-24 2017-08-03 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского" Рекомбинантный таргетный токсин, специфичный к клеткам, экспрессирующим рецептор her2
CA3030208A1 (en) 2016-08-11 2018-02-15 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin binding proteins
ES2953516T3 (es) 2016-09-22 2023-11-14 Molecular Partners Ag Proteínas de unión recombinantes y su uso
JP7685735B2 (ja) 2016-12-02 2025-05-30 アンヘレス セラピューティクス インコーポレイテッド 合成免疫受容体およびその使用方法
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
CA3123986A1 (en) 2018-12-18 2020-06-25 Navigo Proteins Gmbh Novel folr1 specific binding proteins for cancer diagnosis and treatment
JP7611173B2 (ja) * 2019-06-04 2025-01-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えｆａｐ結合タンパク質及びそれらの使用
CN114222757A (zh) * 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
CA3138805A1 (en) * 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
EP3980443A1 (en) 2019-06-04 2022-04-13 Molecular Partners AG Multispecific proteins
US12240913B2 (en) 2019-07-26 2025-03-04 Abl Bio Inc. Anti-HER2/anti-4-1BB bispecific antibody and use thereof
BR112022011177A2 (pt) * 2019-12-11 2022-09-27 Molecular Partners Ag Domínios de repetição de anquirina projetados com resíduos de superfície alterados
WO2021224686A1 (en) 2020-05-06 2021-11-11 Molecular Partners Ag Novel ankyrin repeat binding proteins and their uses
WO2021229076A1 (en) * 2020-05-14 2021-11-18 Molecular Partners Ag Recombinant cd40 binding proteins and their use
EP4149959A1 (en) 2020-05-14 2023-03-22 Molecular Partners AG Multispecific proteins
CA3202358A1 (en) 2020-12-16 2022-06-23 Andreas BOSSHART Novel slow-release prodrugs
IL305677A (en) 2021-03-09 2023-11-01 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
US20240150475A1 (en) 2021-03-09 2024-05-09 Molecular Partners Ag Novel darpin based cd123 engagers
JP2024509890A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト プロテアーゼ切断可能なプロドラッグ
JP2024508969A (ja) 2021-03-09 2024-02-28 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ
EP4447990A1 (en) 2021-12-14 2024-10-23 Molecular Partners AG Designed repeat domains with dual binding specificity and their use
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
EP4673159A1 (en) 2023-02-27 2026-01-07 Molecular Partners AG Darpins for use in reducing renal accumulation of drugs
WO2024251628A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
JP4086325B2 (ja) 1997-04-23 2008-05-14 プリュックテュン，アンドレアス 標的分子と相互作用する（ポリ）ペプチドをコードする核酸分子の同定方法
PT1137812E (pt) 1998-12-02 2007-05-31 Adnexus Therapeutics Inc Fusões adn-proteína e suas utilizações
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
AU2005249396B2 (en) * 2004-05-05 2011-10-20 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
HRP20141111T1 (hr) * 2004-07-22 2015-01-02 Genentech, Inc. Sastav her2-protutijela
MX2008000345A (es) 2005-07-08 2008-04-02 Univ Zuerich Visualizacion en fagos usando transcolocacion contraduccional de polipeptidos de fusion.
DK2402754T4 (da) 2006-03-06 2023-08-28 Amunix Operating Inc Ustrukturerede rekombinante polymerer og anvendelser deraf
JP5351889B2 (ja) 2007-06-21 2013-11-27 テクニシェ ユニバーシタット ミュンヘン インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
WO2009068631A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
MX359570B (es) 2008-11-03 2018-10-01 Molecular Partners Ag Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CN113278077A (zh) 2010-11-26 2021-08-20 分子组合公司 设计的与血清白蛋白结合的重复蛋白
WO2012149439A2 (en) 2011-04-29 2012-11-01 Janssen Biotech, Inc. Il4/il13 binding repeat proteins and uses
WO2012162418A1 (en) * 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands
EP2867360B1 (en) 2012-06-28 2019-05-08 Molecular Partners AG Designed ankyrin repeat proteins binding to platelet-derived growth factor
CA2883264A1 (en) 2012-10-15 2014-04-24 Universitat Zurich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白

Also Published As

Publication number Publication date
RU2015120663A (ru) 2017-01-10
WO2014083208A1 (en) 2014-06-05
RU2664464C9 (ru) 2018-12-19
EP2925784A1 (en) 2015-10-07
AU2013351096A1 (en) 2015-07-09
KR102290592B1 (ko) 2021-08-19
AU2013351096C9 (en) 2019-01-31
AU2013351096B2 (en) 2018-08-09
HK1211297A1 (zh) 2016-05-20
BR112015012436A2 (pt) 2017-09-12
CA2892747C (en) 2022-07-19
AU2013351096C1 (en) 2018-11-08
US10370414B2 (en) 2019-08-06
JP2015537044A (ja) 2015-12-24
EP2738180A1 (en) 2014-06-04
US20150299265A1 (en) 2015-10-22
CA2892747A1 (en) 2014-06-05
AU2018256592A1 (en) 2018-11-22
WO2014083208A9 (en) 2014-12-24
EP2925784B1 (en) 2021-02-17
RU2664464C2 (ru) 2018-08-17
WO2014083208A8 (en) 2014-10-30
MX2015006548A (es) 2015-10-15
CN104918959A (zh) 2015-09-16
JP6410724B2 (ja) 2018-10-24
KR20150091138A (ko) 2015-08-07

Similar Documents

Publication Publication Date Title
MX2015006548A (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
CY1119567T1 (el) Θεραπευτικα πεπτιδια
IN2012DN00640A (es)
EA201291065A1 (ru) Антитела против vla-4
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
PH12012502115A1 (en) Modified binding proteins inhibiting the vegf-a receptor interaction
MY164906A (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
BR112014019579A2 (pt) Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
NZ714128A (en) 4-1bb binding molecules
UA110049C2 (uk) ЛІКУВАННЯ ОСТЕОАРТРИТУ ІМУНОГЛОБУЛІНОВИМ ЗВ'ЯЗУВАЛЬНИМ БІЛКОМ З ПОДВІЙНИМ ВАРІАБЕЛЬНИМ ДОМЕНОМ, ЩО ЗВ'ЯЗУЄ IL-1α І IL-1β
UA106900C2 (uk) Агоністичний dr5-зв'язувальний поліпептид
EA201690314A1 (ru) Анти-garp-белок и его применения
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.
MX2011008752A (es) Variantes de union a anti-albumina de suero mejoradas.
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
PH12014501818A1 (en) Pseudomonas aeruginosa pcrv binding single variable domain antibodies
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2015013803A (es) Proteina de fusion de enlace al cartilago.
MX2011008749A (es) Variantes de union a anti-albumina de suero mejoradas.
PH12019500677A1 (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
NZ700274A (en) Anti-pdgf-c antibodies
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы

Legal Events

Date Code Title Description
FG Grant or registration